Association Between Medicaid Expansion and Rates of Opioid-Related Hospital Use.


Journal

JAMA internal medicine
ISSN: 2168-6114
Titre abrégé: JAMA Intern Med
Pays: United States
ID NLM: 101589534

Informations de publication

Date de publication:
01 05 2020
Historique:
pubmed: 24 3 2020
medline: 21 1 2021
entrez: 24 3 2020
Statut: ppublish

Résumé

The rate of opioid-related emergency department (ED) visits and inpatient hospitalizations has increased rapidly in recent years. Medicaid expansions have the potential to reduce overall opioid-related hospital events by improving access to outpatient treatment for opioid use disorder. To examine the association between Medicaid expansions and rates of opioid-related ED visits and inpatient hospitalizations. A difference-in-differences observational design was used to compare changes in opioid-related hospital events in US nonfederal, nonrehabilitation hospitals in states that implemented Medicaid expansions between the first quarter of 2005 and the last quarter of 2017 with changes in nonexpansion states. All-payer ED and hospital discharges from 45 states in the Healthcare Cost and Utilization Project FastStats were included. State implementation of Medicaid expansions between 2005 and 2017. Rates of all opioid-related ED visits and inpatient hospitalizations, measured as the quarterly numbers of treat-and-release ED discharges and hospital discharges related to opioid abuse, dependence, and overdose, per 100 000 state population. In the 46 states and District of Columbia included in the study, 1524 observations of emergency department data and 2219 observations of opioid-related inpatient hospitalizations were analyzed. The post-2014 Medicaid expansions were associated with a 9.74% (95% CI, -18.83% to -0.65%) reduction in the rate of opioid-related inpatient hospitalizations. There appeared to be no association between the pre-2014 or post-2014 Medicaid expansions and the rate of opioid-related ED visits (post-2014 Medicaid expansions, -3.98%; 95% CI, -14.69% to 6.72%; and pre-2014 Medicaid expansions, 1.02%; 95% CI, -5.25% to 7.28%). Medicaid expansion appears to be associated with meaningful reductions in opioid-related hospital use, possibly attributable to improved care for opioid use disorder in other settings.

Identifiants

pubmed: 32202609
pii: 2763182
doi: 10.1001/jamainternmed.2020.0473
pmc: PMC7091455
doi:

Substances chimiques

Analgesics, Opioid 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

753-759

Subventions

Organisme : NIDA NIH HHS
ID : K01 DA042139
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Références

Med Care. 2017 Apr;55(4):336-341
pubmed: 28296674
Health Serv Res. 2012 Jun;47(3 Pt 1):939-62
pubmed: 22299673
Health Aff (Millwood). 2006 May-Jun;25(3):w204-16
pubmed: 16638792
Health Aff (Millwood). 2015 Jun;34(6):1028-34
pubmed: 26056209
N Engl J Med. 2014 May 29;370(22):2063-6
pubmed: 24758595
Health Aff (Millwood). 2018 Aug;37(8):1208-1215
pubmed: 30080455
Annu Rev Public Health. 2018 Apr 1;39:453-469
pubmed: 29328877
J Policy Anal Manage. 2019;38(2):366-93
pubmed: 30882195
JAMA Netw Open. 2018 Aug 3;1(4):e181588
pubmed: 30646116
Health Aff (Millwood). 2018 Aug;37(8):1216-1222
pubmed: 30080460
Health Serv Res. 2015 Dec;50(6):1734-50
pubmed: 26445915
J Gen Intern Med. 2019 Nov;34(11):2313-2315
pubmed: 31313114
Health Aff (Millwood). 2011 Feb;30(2):284-92
pubmed: 21289350
Milbank Q. 2015 Sep;93(3):561-83
pubmed: 26350930
MMWR Morb Mortal Wkly Rep. 2018 Jan 04;67(5152):1419-1427
pubmed: 30605448
Health Serv Res. 2015 Dec;50(6):1787-809
pubmed: 26551430
J Health Econ. 2018 Jul;60:177-197
pubmed: 29990675
N Engl J Med. 2006 Jul 27;355(4):365-74
pubmed: 16870915
Am J Public Health. 2015 Aug;105(8):e55-63
pubmed: 26066931
Ann Emerg Med. 2017 Aug;70(2):215-225.e6
pubmed: 28641909
Ann Intern Med. 2018 Aug 7;169(3):137-145
pubmed: 29913516
MMWR Morb Mortal Wkly Rep. 2017 Jul 07;66(26):697-704
pubmed: 28683056
Health Aff (Millwood). 2016 Jan;35(1):106-10
pubmed: 26733707
Science. 2014 Jan 17;343(6168):263-8
pubmed: 24385603
Health Aff (Millwood). 2014 Jan;33(1):78-87
pubmed: 24395938
Drug Alcohol Depend. 2015 Dec 1;157:36-43
pubmed: 26483356
Health Aff (Millwood). 2018 Jan;37(1):111-120
pubmed: 29309219
J Law Med Ethics. 2018 Jun;46(2):272-278
pubmed: 30147002

Auteurs

Hefei Wen (H)

Harvard Pilgrim Health Care Institute, Division of Health Policy and Insurance Research, Department of Population Medicine, Harvard Medical School, Boston, Massachusetts.

Aparna Soni (A)

School of Public Affairs, Department of Public Administration and Policy, American University, Washington, DC.

Alex Hollingsworth (A)

O'Neill School of Public and Environmental Affairs, Indiana University, Bloomington, Indiana.

Seth Freedman (S)

O'Neill School of Public and Environmental Affairs, Indiana University, Bloomington, Indiana.

Joseph Benitez (J)

College of Public Health, Department of Health Management & Policy, University of Kentucky, Lexington, Kentucky.

Kosali Simon (K)

O'Neill School of Public and Environmental Affairs, Indiana University, Bloomington, Indiana.
National Bureau of Economic Research, Cambridge, Massachusetts.

Brendan Saloner (B)

Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH